Drug Profile
Choline fenofibrate - AbbVie
Alternative Names: ABT-335; Fenofibric acid choline salt; HEXA/ABT335; SLV 348; SLV348/ABT335; TriLipixLatest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Solvay
- Developer AbbVie
- Class Antihyperlipidaemics; Chlorobenzenes; Ethanolamines; Fibric acid derivatives; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperlipidaemia
- Discontinued Diabetic macular oedema
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-II for Diabetic macular oedema in European Union (PO)
- 07 Sep 2021 Discontinued - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)
- 12 Oct 2015 No recent reports on development identified - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)